Disseminated Brown Tumors from Hyperparathyroidism Masquerading as Metastatic Cancer: A Complication of Parathyroid Carcinoma

Gupta, Anju; Horattas, Mark C.; Moattari, Ali Reza; Shorten, Scott D.
October 2001
American Surgeon;Oct2001, Vol. 67 Issue 10, p951
Academic Journal
Osteitis fibrosa cystica (brown tumors) can be a skeletal manifestation of advanced hyperparathyroidism, including parathyroid cancer. Severe osteitis fibrosa cystica can mimic metastatic bone diseases especially in patients with a history of cancer. Because the treatment and prognosis of these two problems differ greatly considering hyperparathyroidism in the differential diagnosis of patients found to have osteolytic lesions is critical for the appropriate management of these patients. In this case report we describe a patient with a history of renal cell cancer and presumed osteolytic bone metastases. During prophylactic intramedullary rodding to prevent pathologic fracture of her femur she was found to have a benign lesion related to her previously undiagnosed hyperparathyroidism caused by an underlying parathyroid cancer. A detailed review of this disease and the associated bone changes is also included to underscore the importance of an adequate differential diagnosis as well as optimal management. Patients with hypercalcemia or bony lesions should not automatically be treated palliatively for metastatic disease just because of a past medical history of cancer. Hyperparathyroidism is a readily curable problem if properly diagnosed.


Related Articles

  • Secondary Hyperparathyroidism: Evidence for an Association with Papillary Thyroid Cancer. Klyachkin, Michael L.; Sloan, David A. // American Surgeon;May2001, Vol. 67 Issue 5, p397 

    The association between primary hyperparathyroidism and nonmedullary thyroid malignancies is well known. There is also, however, some evidence for an association between secondary hyperparathyroidism (SHPT) and thyroid cancer. We report three patients in whom invasive papillary thyroid carcinoma...

  • Downregulated parafibromin expression is a promising marker for pathogenesis, invasion, metastasis and prognosis of gastric carcinomas. Hua-chuan Zheng; Hiroyuki Takahashi; Xiao-han Li; Takuo Hara; Shinji Masuda; Yi-fu Guan; Yasuo Takano // Virchows Archiv;Feb2008, Vol. 452 Issue 2, p147 

    Abstract  Parafibromin is a protein encoded by the hyperparathyroidism 2 oncosuppressor gene and its downregulated expression is involved in pathogenesis of parathyroid carcinomas. To clarify the roles of parafibromin expression in tumourigenesis and progression of gastric...

  • Cinacalcet Does Not Affect the Activity of Cytochrome P450 3A Enzymes, a Metabolic Pathway for Common Immunosuppressive Agents: A Randomized, Open-Label, Crossover, Single-Centre Study in Healthy Volunteers. Padhi, Desmond; Salfi, Maggi; Emery, Maurice // Drugs in R&D;2008, Vol. 9 Issue 5, p335 

    BACKGROUND: and objective: Cinacalcet HCl (cinacalcet) is approved for the treatment of secondary hyperparathyroidism in subjects receiving dialysis and for the reduction of hypercalcaemia in patients with parathyroid carcinoma. The drug may also be co-administered with medications used in the...

  • 2009 EANM parathyroid guidelines. Hindié, Elif; Ugur, Ömer; Fuster, David; O'Doherty, Michael; Grassetto, Gaia; Ureña, Pablo; Kettle, Andrew; Gulec, Seza A.; Pons, Francesca; Rubello, Domenico // European Journal of Nuclear Medicine & Molecular Imaging;Jul2009, Vol. 36 Issue 7, p1201 

    The present guidelines were issued by the Parathyroid Task Group of the European Association of Nuclear Medicine. The main focus was imaging of primary hyperparathyroidism. Dual-tracer and single-tracer parathyroid scintigraphy protocols were discussed as well as the various modalities of image...

  • Cancer of ectopic parathyroid gland presentation of the disease with a case report. Pesovic, Jovan P.; Milosevic, Bojan Z.; Canovic, Dragan S.; Cvetkovic, Aleksandar M.; Milosavljevic, Milos Z.; Jevdjic, Jasna D.; Pavlovic, Mladen D.; Petrovic, Marko D. // International Journal of Clinical & Experimental Medicine;2013, Vol. 6 Issue 3, p227 

    Tc-99m-methoxyisobutylisonitril (MIBI) scintigraphy is localizing diagnostic methods that is used for detection of sicken parathyroid gland (PT). The use of this method for PT diseases diagnosis makes surgical treatment of a patient more successful. This is a report about the patient who was...

  • Parathyroid Four-Dimensional Computed Tomography: Evaluation of Radiation Dose Exposure During Preoperative Localization of Parathyroid Tumors in Primary Hyperparathyroidism. Mahajan, Amit; Starker, Lee; Ghita, Monica; Udelsman, Robert; Brink, James; Carling, Tobias // World Journal of Surgery;Jun2012, Vol. 36 Issue 6, p1335 

    Background: Parathyroid four-dimensional computed tomography (4DCT) provides greater sensitivity than sestamibi with single photon emission CT (SPECT, or SeS) for preoperative localization of parathyroid tumors in patients with primary hyperparathyroidism (PHPT). The radiation dose imparted to...

  • Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. Campennì, Alfredo; Ruggeri, Rosaria; Sindoni, Alessandro; Giovinazzo, Salvatore; Calbo, Enrico; Ieni, Antonio; Calbo, Letterio; Tuccari, Giovanni; Baldari, Sergio; Benvenga, Salvatore // Journal of Bone & Mineral Metabolism;May2012, Vol. 30 Issue 3, p367 

    Parathyroid carcinoma (PC) is a rare malignancy, with an indolent but progressive course. Long-term survival is largely dependent on the extent of the primary surgical resection. Hence, pre- or intraoperative suspicion of malignancy is of great importance. We describe the case of a 62-year-old...

  • Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review. Komaba, Hirotaka; Takeda, Yoko; Shin, Jeongsoo; Tanaka, Reika; Kakuta, Takatoshi; Tominaga, Yoshihiro; Fukagawa, Masafumi // NDT Plus;Aug2008 Supplement 3, Vol. 1, piii54 

    Parathyroid hormone (PTH) levels detected by intact PTH assays are generally higher than those detected by the whole PTH assay because the latter does not detect non-(1–84) PTH fragments, mainly PTH (7–84). Rare exceptions to this rule have been reported in patients with severe...

  • Clinical Importance of Calcium-Sensing Receptor Gene Polymorphism Arg990Gly in the Age of Calcimimetic Therapy. Rothe, Hansjörg; Mayer, Gert // Current Pharmacogenomics;Jun2006, Vol. 4 Issue 2, p153 

    Cinacalcet HCl is the first calcimimetic agent available for the therapy of secondary hyperparathyroidism (sHPT) and palliative treatment of parathyroid carcinoma. It acts on the extracellular calcium-sensing receptor (CaSR) as an allosteric activator, i.e. it leads to responses as if...

  • Circulating PTH molecular forms: What we know and what we don't. D'Amour, P // Kidney International Supplement;Jul2006, Issue 102, pS29 

    Circulating parathyroid hormone (PTH) molecular forms have been identified by three generations of PTH assays after gel chromatography or high-performance liquid chromatography fractionation of serum. Carboxyl-terminal (C) fragments missing the amino-terminal (N) structure of PTH(1–84)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics